dalteparin has been researched along with Osteoarthritis in 3 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 9.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 5.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group." | 2.84 | Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017) |
| " The purpose of this study was to assess the impact of the route of administration and dosage regimen on the compliance to the prescription." | 1.56 | Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study. ( Bautista, M; Bonilla, G; Castro, J; Llinás, A; Moreno, JP, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sidhu, VS | 1 |
| Kelly, TL | 1 |
| Pratt, N | 1 |
| Graves, SE | 1 |
| Buchbinder, R | 1 |
| Adie, S | 1 |
| Cashman, K | 1 |
| Ackerman, I | 1 |
| Bastiras, D | 1 |
| Brighton, R | 1 |
| Burns, AWR | 1 |
| Chong, BH | 1 |
| Clavisi, O | 1 |
| Cripps, M | 1 |
| Dekkers, M | 1 |
| de Steiger, R | 1 |
| Dixon, M | 1 |
| Ellis, A | 1 |
| Griffith, EC | 1 |
| Hale, D | 1 |
| Hansen, A | 1 |
| Harris, A | 1 |
| Hau, R | 1 |
| Horsley, M | 1 |
| James, D | 1 |
| Khorshid, O | 1 |
| Kuo, L | 1 |
| Lewis, P | 1 |
| Lieu, D | 1 |
| Lorimer, M | 1 |
| MacDessi, S | 1 |
| McCombe, P | 1 |
| McDougall, C | 1 |
| Mulford, J | 1 |
| Naylor, JM | 1 |
| Page, RS | 1 |
| Radovanovic, J | 1 |
| Solomon, M | 1 |
| Sorial, R | 1 |
| Summersell, P | 1 |
| Tran, P | 1 |
| Walter, WL | 1 |
| Webb, S | 1 |
| Wilson, C | 1 |
| Wysocki, D | 1 |
| Harris, IA | 1 |
| Moreno, JP | 1 |
| Bautista, M | 1 |
| Castro, J | 1 |
| Bonilla, G | 1 |
| Llinás, A | 1 |
| Xie, J | 1 |
| Ma, J | 1 |
| Huang, Q | 1 |
| Yue, C | 1 |
| Pei, F | 1 |
2 trials available for dalteparin and Osteoarthritis
| Article | Year |
|---|---|
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Aust | 2022 |
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa | 2017 |
1 other study available for dalteparin and Osteoarthritis
| Article | Year |
|---|---|
Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Repl | 2020 |